Ipsen is a global specialty-driven pharmaceutical group selling in excess of 20 drug types in more than 115 countries with an R&D expenditure of around €193 million.
Ipsen’s ambition is to be a leader in specialty healthcare solutions for targeted debilitating diseases. This strategy called for the consolidation of their research in the heart of leading biotechnological and life sciences hubs.
Ipsen had undertaken a preliminary study which sought to define broad proposals for accommodating their Oxford research group, at Milton Park. They then appointed Austin to undertake a critique of these proposals, to develop them into a viable detailed design and to deliver this 2700m² prestigious science facility.

`Austin’s team have delivered a superb new laboratory and office space in which Ipsen’s UK R&D team are now located. From the design process and through the construction Phase, Austin have listened to the needs of the Ipsen team and understood the vision for the new site.  The laboratory requirements were challenging, and yet the construction phase has been completed within eight months, on time to accept the personnel transferring from other Ipsen UK sites.’ – John Chaddock, VP Neurology Site Head, Ipsen Bioinnovation.

  • architecture
  • mechanical
  • electrical
  • structural
  • public health
  • construction
  • management